Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 24 Kidney Neoplasms 8 Parkinson Disease 4, Autosomal Dominant Lewy Body 5 von Hippel-Lindau Disease 4 Pheochromocytoma 2 Paraganglioma 2 Neoplasm Metastasis 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Recurrence 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Neuroectodermal Tumors, Primitive 1 Neoplasms 1 Metastatic Castration-Resistant Prostate Cancer 1 Hemangioblastoma 1 Glioblastoma 1 Endometrial Neoplasms 1 Clear-cell metastatic renal cell carcinoma 1 Carcinoma 1 Breast Neoplasms 1 Adenoma, Islet Cell 1

Interventions

Trastuzumab 594 Paclitaxel 561 Cyclophosphamide 545 Docetaxel 478 Capecitabine 387 Letrozole 350 Fulvestrant 310 Doxorubicin 285 Carboplatin 277 Tamoxifen 257 Anastrozole 219 exemestane 211 Epirubicin 210 Radiotherapy 197 Bevacizumab 189 pertuzumab 175 Gemcitabine 163 Vinorelbine 162 pembrolizumab 161 Lapatinib 161 palbociclib 152 Exercise 132 Fluorouracil 118 Albumin-Bound Paclitaxel 116 eribulin 108 Magnetic Resonance Spectroscopy 108 130-nm albumin-bound paclitaxel 107 Everolimus 103 Taxes 96 Cisplatin 92

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Breast Neoplasms × belzutifan × Clear all

NCT06428396 2026-05-18

LITESPARK-029

Merck Sharp & Dohme LLC

Phase 2 Recruiting

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡